S212 A Phase 2 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults With Moderately to Severely Active …
1. 请及时下载文件确认是否正确, 系统将在 2026-04-10 10:42:06 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
D Binion, BG Feagan, E Mortensen…
Official journal of the …, 2023
journals.lww.com
Methods: Patients will be randomized 1: 1 to receive DPL or PBO. Key inclusion criteria include age≥ 18 years, moderately to severely active UC (modified Mayo score 5–9), biomarker enrichment, and inadequate/non-response, loss of response, or intolerance to standard biologic therapy and/or oral corticosteroids, ASA compounds, immunomodulators, or small molecules. Key exclusion criteria include severe extensive colitis (current hospitalization, likely to require surgery for UC within 12 weeks of screening), prior medical …
